805 related articles for article (PubMed ID: 18632147)
21. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis.
Lovell DJ; Ruperto N; Goodman S; Reiff A; Jung L; Jarosova K; Nemcova D; Mouy R; Sandborg C; Bohnsack J; Elewaut D; Foeldvari I; Gerloni V; Rovensky J; Minden K; Vehe RK; Weiner LW; Horneff G; Huppertz HI; Olson NY; Medich JR; Carcereri-De-Prati R; McIlraith MJ; Giannini EH; Martini A; ;
N Engl J Med; 2008 Aug; 359(8):810-20. PubMed ID: 18716298
[TBL] [Abstract][Full Text] [Related]
22. Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial.
Westhovens R; Cole JC; Li T; Martin M; Maclean R; Lin P; Blaisdell B; Wallenstein GV; Aranda R; Sherrer Y
Rheumatology (Oxford); 2006 Oct; 45(10):1238-46. PubMed ID: 16567357
[TBL] [Abstract][Full Text] [Related]
23. Investigation into the impact of abatacept on sleep quality in patients with rheumatoid arthritis, and the validity of the MOS-Sleep questionnaire Sleep Disturbance Scale.
Wells G; Li T; Tugwell P
Ann Rheum Dis; 2010 Oct; 69(10):1768-73. PubMed ID: 20610444
[TBL] [Abstract][Full Text] [Related]
24. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.
Kremer JM; Genant HK; Moreland LW; Russell AS; Emery P; Abud-Mendoza C; Szechinski J; Li T; Ge Z; Becker JC; Westhovens R
Ann Intern Med; 2006 Jun; 144(12):865-76. PubMed ID: 16785475
[TBL] [Abstract][Full Text] [Related]
25. Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial.
Brunner HI; Ruperto N; Tzaribachev N; Horneff G; Chasnyk VG; Panaviene V; Abud-Mendoza C; Reiff A; Alexeeva E; Rubio-Pérez N; Keltsev V; Kingsbury DJ; Del Rocio Maldonado Velázquez M; Nikishina I; Silverman ED; Joos R; Smolewska E; Bandeira M; Minden K; van Royen-Kerkhof A; Emminger W; Foeldvari I; Lauwerys BR; Sztajnbok F; Gilmer KE; Xu Z; Leu JH; Kim L; Lamberth SL; Loza MJ; Lovell DJ; Martini A;
Ann Rheum Dis; 2018 Jan; 77(1):21-29. PubMed ID: 28507219
[TBL] [Abstract][Full Text] [Related]
26. Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis.
Lovell DJ; Giannini EH; Reiff AO; Kimura Y; Li S; Hashkes PJ; Wallace CA; Onel KB; Foell D; Wu R; Biedermann S; Hamilton JD; Radin AR
Arthritis Rheum; 2013 Sep; 65(9):2486-96. PubMed ID: 23754188
[TBL] [Abstract][Full Text] [Related]
27. Abatacept in the treatment of polyarticular JIA: development, clinical utility, and place in therapy.
Goldzweig O; Hashkes PJ
Drug Des Devel Ther; 2011 Jan; 5():61-70. PubMed ID: 21340039
[TBL] [Abstract][Full Text] [Related]
28. Abatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis.
Zulian F; Balzarin M; Falcini F; Martini G; Alessio M; Cimaz R; Cimino L; Zannin ME
Arthritis Care Res (Hoboken); 2010 Jun; 62(6):821-5. PubMed ID: 20191477
[TBL] [Abstract][Full Text] [Related]
29. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
Cohen SB; Emery P; Greenwald MW; Dougados M; Furie RA; Genovese MC; Keystone EC; Loveless JE; Burmester GR; Cravets MW; Hessey EW; Shaw T; Totoritis MC;
Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
[TBL] [Abstract][Full Text] [Related]
30. Intravenous abatacept in Japanese patients with polyarticular-course juvenile idiopathic arthritis: results from a phase III open-label study.
Hara R; Umebayashi H; Takei S; Okamoto N; Iwata N; Yamasaki Y; Nakagishi Y; Kizawa T; Kobayashi I; Imagawa T; Kinjo N; Amano N; Takahashi Y; Mori M; Itoh Y; Yokota S
Pediatr Rheumatol Online J; 2019 Apr; 17(1):17. PubMed ID: 31039807
[TBL] [Abstract][Full Text] [Related]
31. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial.
Burmester GR; Blanco R; Charles-Schoeman C; Wollenhaupt J; Zerbini C; Benda B; Gruben D; Wallenstein G; Krishnaswami S; Zwillich SH; Koncz T; Soma K; Bradley J; Mebus C;
Lancet; 2013 Feb; 381(9865):451-60. PubMed ID: 23294500
[TBL] [Abstract][Full Text] [Related]
32. Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes.
Bathon J; Robles M; Ximenes AC; Nayiager S; Wollenhaupt J; Durez P; Gomez-Reino J; Grassi W; Haraoui B; Shergy W; Park SH; Genant H; Peterfy C; Becker JC; Covucci A; Moniz Reed D; Helfrick R; Westhovens R
Ann Rheum Dis; 2011 Nov; 70(11):1949-56. PubMed ID: 21821865
[TBL] [Abstract][Full Text] [Related]
33. Subcutaneous abatacept for the treatment of rheumatoid arthritis: longterm data from the ACQUIRE trial.
Genovese MC; Tena CP; Covarrubias A; Leon G; Mysler E; Keiserman M; Valente R; Nash P; Simon-Campos JA; Box J; Legerton CW; Nasonov E; Durez P; Delaet I; Teng J; Alten R
J Rheumatol; 2014 Apr; 41(4):629-39. PubMed ID: 24584926
[TBL] [Abstract][Full Text] [Related]
34. Abatacept.
Hervey PS; Keam SJ
BioDrugs; 2006; 20(1):53-61; discussion 62. PubMed ID: 16573350
[TBL] [Abstract][Full Text] [Related]
35. Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors.
Genovese MC; Fleischmann RM; Greenwald M; Satterwhite J; Veenhuizen M; Xie L; Berclaz PY; Myers S; Benichou O
Ann Rheum Dis; 2013 Sep; 72(9):1461-8. PubMed ID: 23268367
[TBL] [Abstract][Full Text] [Related]
36. Role of abatacept in the management of rheumatoid arthritis.
Nogid A; Pham DQ
Clin Ther; 2006 Nov; 28(11):1764-78. PubMed ID: 17212998
[TBL] [Abstract][Full Text] [Related]
37. Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial.
Cope AP; Jasenecova M; Vasconcelos JC; Filer A; Raza K; Qureshi S; D'Agostino MA; McInnes IB; Isaacs JD; Pratt AG; Fisher BA; Buckley CD; Emery P; Ho P; Buch MH; Ciurtin C; van Schaardenburg D; Huizinga T; Toes R; Georgiou E; Kelly J; Murphy C; Prevost AT;
Lancet; 2024 Mar; 403(10429):838-849. PubMed ID: 38364839
[TBL] [Abstract][Full Text] [Related]
38. Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life.
Emery P; Kosinski M; Li T; Martin M; Williams GR; Becker JC; Blaisdell B; Ware JE; Birbara C; Russell AS
J Rheumatol; 2006 Apr; 33(4):681-9. PubMed ID: 16568505
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial.
Mease P; Coates LC; Helliwell PS; Stanislavchuk M; Rychlewska-Hanczewska A; Dudek A; Abi-Saab W; Tasset C; Meuleners L; Harrison P; Besuyen R; Van der Aa A; Mozaffarian N; Greer JM; Kunder R; Van den Bosch F; Gladman DD
Lancet; 2018 Dec; 392(10162):2367-2377. PubMed ID: 30360969
[TBL] [Abstract][Full Text] [Related]
40. Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial.
Brunner HI; Foeldvari I; Alexeeva E; Ayaz NA; Calvo Penades I; Kasapcopur O; Chasnyk VG; Hufnagel M; Żuber Z; Schulert G; Ozen S; Rakhimyanova A; Ramanan A; Scott C; Sozeri B; Zholobova E; Martin R; Zhu X; Whelan S; Pricop L; Martini A; Lovell D; Ruperto N;
Ann Rheum Dis; 2023 Jan; 82(1):154-160. PubMed ID: 35961761
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
